News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee proposes changes of the Board of Directors of PledPharma

January 19, 2017

PledPharma AB
Company Announcement

Nomination Committee proposes changes of the Board of Directors of PledPharma

Stockholm, 2017-01-19 08:00 CET (GLOBE NEWSWIRE) -- 
PledPharma today announced that the company's Nomination Committee has
submitted a proposal for a new composition of the Board of Directors for
consideration at an extraordinary shareholders meeting held on February 10,

PledOx®, PledPharma's lead-candidate drug, has in a Phase IIb study shown to
reduce the nerve damage associated with chemotherapy in a significant and
clinically relevant manner. In autumn 2016, the company decided to develop
PledOx® through the final registration studies. Meanwhile, the start of a
clinical study with Aladote® - a candidate drug to reduce liver damage from
paracetamol poisoning is being planned. The Nomination Committee considers that
this implies the need for strengthened competence of the Board in the areas of
Phase III clinical development and registration procedures. 

The Nomination Committee therefore proposes changes to the Board by new
election of Gunilla Osswald and Elisabeth Svanberg. Board members Håkan Åström
(chairman) and Sten Nilsson will remain on the board. 

Gunilla Osswald (born 1961) M.Pharm.Sci., Ph.D.
Gunilla holds a Ph.D. in Biopharmaceutics and Pharmacokinetics and is the CEO
at BioArctic AB. She has extensive experience in drug development including
clinical drug development, in big pharma and biotech, with a documented track
record of project delivery from preclinical to regulatory submission and
launch. She built an innovative Neurodegeneration project portfolio for
AstraZeneca including in- and out-licensing of projects. Gunilla has led
BioArctic to important deliveries including partnering deal with AbbVie, new
contracts with Eisai and funding from Horizon2020 and Vinnova. 

Elisabeth Svanberg (born 1961) MD, Ph.D.
Elisabeth is a general surgeon and associate professor of surgery and Chief
Development Officer at Ixaltis SA, a specialty pharmaceutical company
developing proprietary therapeutics to treat genitourinary (GU) disorders with
unmet medical need. Her career in the pharmaceutical industry started when she
joined Serono International in 2000. Initially in the field of metabolism and
subsequently held roles of increasing responsibilities before joining Bristol
Myers Squibb (BMS) in the United States in 2007 serving as development leader a
first in class novel diabetes medicine and as Head of Medical Affairs for the
Intercontinental region. Between 2014-2016 Elisabeth worked at Janssen
Pharmaceuticals (a Johnson & Johnson Company) as Vice President, Head of the
Established Products group managing a portfolio of 90 products, used by an
estimated 150 million patients globally. 

The Nomination Committee consists of Staffan Persson (Chairman), Peter Lindell,
Astrid Samuelsson and Håkan Åström (Adjunct). 

For further information, please contact:

Staffan Persson, Chairman of Nomination Committee

Tel: +46 703 21 00 98

Håkan Åström, Chairman of the Board

Tel: +46 703 74 72 13

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® reduces nerve damage
associated with chemotherapy and positive results from the Phase IIb study
PLIANT were presented during the spring of 2015. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First
North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80
00). For more information, see 

This information is information that PledPharma AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities Markets
Act. The information was submitted for publication, through the agency of the
contact person set out above, at CET 8:00 on January 19, 2017.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10